MTOR and breast carcinoma: Furthermore, with regard to pathway activation status itself, the PI3K/AKT/mTOR pathway is known to be significantly more upregulated in TNBC as compared to other receptor subtypes of breast cancer (187–189), and is known to contribute to both hormonal therapy resistance as well as chemotherapy resistance.